| 公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
1 | 2005 | A non-internalizing anti-CD40 antibody, CHIR-12.12, blocks CD40L-induced cytokine production and mediates greater ADCC than rituximab in primary CLL cells | Tong, X.; Aukerman, S. L.; Lin, K.; Aziz, N.; Goldbeck, C.; Georgakis, G. V.; Younes, G.; Wen-Kai Weng ; O'Brien, S.; Wierda, W.; Jallal, B.; Luqman, M. | Blood | | |
2 | 2005 | A polymorphism in the C1qA component of complement correlates with prolonged complete remission following rituximab therapy of follicular lymphoma | Racila, E.; Wen-Kai Weng ; Wooldridge, J. E.; Link, B. K.; Levy, R.; Weiner, G. J. | Blood | | |
3 | 2005 | Rituximab variants with re-engineered Fc with higher affinity to activating Fc gamma R eliminate the functional difference between Fc gamma R genotypes | Wen-Kai Weng ; Stavenhagen, J.; Koenig, S.; Levy, R. | Blood | | |
4 | 2005 | Genetic polymorphism of the inhibitory IgG Fc receptor Fc gamma RIIb is not associated with clinical outcome of rituximab treated follicular lymphoma patients | Wen-Kai Weng ; Levy, R. | Blood | | |
5 | 2005 | Enhancing the performance of organic light-emitting devices by selective thermal treatment | Sun, M. C.; Jou, J. H.; Wen-Kai Weng ; Huang, Y. S. | Thin Solid Films | | |
6 | 2005 | Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |
7 | 2005 | Use of dendritic cells and GM-CSF adjuvant are associated with anti-idiotype cellular immune response following idiotype vaccination in follicular lymphoma patients | Wen-Kai Weng ; Czerwinski, D.; Levy, R. | Blood | | |